虹素的抗癌潜力:准TrxR引发ROS介导的亡和烧亡
Qifeng Zhang1, Xinyan Wang1, Gegen Tana1
1Key Laboratory for Candidate Drug Design and Screening Based on Chemical Biology, College of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, People's Republic of China.
Anti-cancer agents in medicinal chemistry
|January 17, 2025
概括
虹素通过抑制硫素还原酶 (TrxR) 来表现出抗癌活性,导致活性氧物种 (ROS) 增加,并在癌细胞中诱导亡和亡. 这种化合物显示出作为一种新型抗瘤药物的潜力.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 来自Semen Irisis的Irisquinone是众所周知的放射治疗敏感剂,用于各种癌症.
- 其精确的抗癌机制在很大程度上仍未被阐明.
研究的目的:
- 为了研究虹素的抗瘤作用.
- 阐明Irisquinone作用的潜在分子机制.
主要方法:
- 通过CCK-8试验评估细胞活力和增殖.
- 使用Fast-TRFS和DTNB试验评估的铁素还原酶 (TrxR) 抑制.
- 用DCFH-DA探测器测量反应性氧物种 (ROS) 的水平.
- 通过Annexin V-FITC/PI染色和西部涂抹分析的亡和烧亡.
主要成果:
- 虹对癌症细胞系表现出显著的抗增殖作用,对正常细胞的毒性最小.
- 虹素对TrxR的抑制导致细胞内ROS生成的增加.
- 升高的ROS激活了BAX和caspase-1,在癌细胞中诱导了亡和热亡.
结论:
- 虹素通过抑制TrxR来发挥抗癌活性,这是触发ROS介导的亡和亡的机制.
- 这些发现支持Irisquinone作为一种新型抗瘤治疗剂的潜在发展.
相关概念视频
Experimental RNAi
6.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.0K
The Intrinsic Apoptotic Pathway
6.3K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.3K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Electron Transport Chain: Complex I and II
10.8K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
10.8K
The Extrinsic Apoptotic Pathway
6.2K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.2K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K


